Abbisko and AstraZeneca advance lung cancer drug combo trial
Abbisko Therapeutics and AstraZeneca (NYSE:AZN) entered a strategic collaboration to develop a combination therapy for patients with EGFR-mutated, PD-L1 positive non-small cell lung cancer (NSCLC).










